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Abstract
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a consequence of altered pul-
monary hemodynamics with increased pulmonary blood flow and pressure. The development of pulmonary vascular disease (PVD)
in this patient population is an important concern in determining operative strategy. Early, definitive surgical repair, when possible,
is the best therapy to prevent and treat PVD. However, this is not possible in some patients because they either presented late,
after the development of PVD, or they have complex lesions not amenable to one-step surgical correction, including patients with
single ventricle physiology, who have a continuing risk of developing PVD. These patients represent an important, high-risk
subgroup and many have been considered inoperable. We present a case series of two patients with complex congenital heart
disease and advanced PVD who successfully underwent a treat and repair strategy with aggressive PAH therapies before surgical
correction. Both patients had normalization of pulmonary vascular resistance prior to surgical correction. Caution is warranted in
applying this strategy broadly and long-term follow-up for these patients is crucial. However, this treat and repair strategy may
allow for favorable outcomes among some patients who previously had no therapeutic options.
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Introduction
Despite recent advances in treating pulmonary vascular dis-
ease (PVD), patients with pulmonary arterial hypertension
(PAH) associated with congenital heart disease (CHD) rep-
resent a challenging subpopulation. In fact, CHD remains
one of the most common causes of PVD worldwide.1
Overall, the best therapy for PVD associated with CHD is
definitive early surgical correction.2 Unfortunately in the
developing world, many patients with CHD continue to be
referred late for corrective surgery and up to 20% patients
are considered ‘‘inoperable’’ at presentation, owing to
advanced PVD.3 PVD contributes significantly to periopera-
tive morbidity and mortality as well as subsequent right
heart failure and death years after late biventricular
repair.4,5 In fact, compared to other forms of PAH, survival
is least favorable in the subset of patients that develop PVD
following late repair of CHD.6 This ongoing risk makes
appropriate preoperative evaluation of the pulmonary vas-
culature critical in identifying those patients at risk.
The current American Heart Association (AHA) and
American Thoracic Society (ATS) guidelines for pediatric
pulmonary hypertension (PH) recommend that selected
patient populations undergo cardiac catheterization before
attempted surgical correction.7 In patients with simple shunt
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lesions uncorrected beyond one year and those with more
complex lesions not repaired in the neonatal period, cardiac
catheterization should be considered. It is important to note
that the assessment of preoperative pulmonary vascular
resistance (PVR) and reactivity in patients with congenital
heart disease is challenging.8,9 The AHA/ATS guidelines7 go
on to suggest certain parameters for operability for patients
with left to right shunts. If the indexed pulmonary vascular
resistance (PVRi) is less than 6 WU*m2 or the PVR:systemic
vascular resistance (SVR) ratio is less than 0.3, repair is
suggested. In patients with a PVRi 6 or PVR:SVR 0.3,
no repair is recommended unless acute vasodilator testing
leads to normalization of these values. The guidelines are
necessarily less precise in the case of patients with single
ventricle physiology.
In patients with initially unfavorable hemodynamics for
surgical correction, it is possible to undertake a strategy of
initiating advanced PH therapies with a plan for repeat
preoperative catheterization. Some patients may have
improvement in hemodynamics such that operative repair
may be considered. In the current case series, we present
two cases of patients with significant PVD and CHD.
These patients underwent a ‘‘treat and repair’’ strategy,
novel for patients with complex congenital lesions.
Successful clinical outcomes in these cases highlight the pos-
sibility of decreasing PVR to allow for correction of cardiac
defects in patients previously considered inoperable.
However, this strategy must be applied judiciously and
these patients must be followed long-term to evaluate
outcomes and potential PVD progression. Still, this clinical
strategy may help push the envelope of those patients con-
sidered good candidates for surgical repair.
Case 1: late diagnosis of transposition of the
great arteries with ventricular septal defect
EJ was the full-term product of an uncomplicated preg-
nancy and delivery in Mexico. He was initially diagnosed
with congenital heart disease when he presented at the age of
four months with cyanosis; an echocardiogram performed at
that time revealed a large, unrestrictive ventricular septal
defect (VSD) and D-looped transposition of the great
arteries (D-TGA). He was initially palliated in Mexico
with pulmonary artery banding and was treated medically
with digoxin, furosemide, sildenafil, spironolactone, capto-
pril, and supplemental oxygen. His baseline oxygen satur-
ations were 60–85%. He was significantly growth-restricted
with a weight-for-age Z-score of –2.87 and was wheelchair
bound secondary to extreme fatigue.
He subsequently presented for medical care in the United
States aged five years with an intercurrent respiratory
viral illness and oxygen saturations of 30–40%. He under-
went cardiac catheterization and atrial septostomy at
that time (Table 1). Given his critical condition, the
only measurements were taken with both FiO2 1.0 and
inhaled nitric oxide (iNO) at 20 ppm; the study revealed
significantly elevated mean pulmonary artery pressure
(mPAP) of 45mmHg, a PVRi of 7 WU/m2, and a ratio of
pulmonary to systemic blood flow (Qp:Qs) of 0.76:1.
Systemic oxygen saturation increased after atrial septostomy
from 40% to 60%.
The patient was transferred to our institution, where
triple therapy was initiated with continued sildenafil
0.75mg/kg TID, bosentan titrated to 2mg/kg BID dosing,
and treprostinil subcutaneously titrated to 90 ng/kg/min.
Three months after triple therapy, repeated cardiac catheter-
ization (Table 1) demonstrated improvement in PVRi to
2.1–2.8 WU/m2, decrease in mPAP to 24mmHg, and a
Qp:Qs of 1.8:1.
He underwent operative repair five months after initi-
ation of triple therapy (delayed slightly due to respiratory
illness) with an arterial switch operation, VSD closure, atrial
septal defect closure, and patch augmentation of the
neopulmonary artery. In the perioperative period, his tre-
prostinil therapy was transitioned from subcutaneous to IV,
to obviate potential inconsistent subcutaneous absorption
while on cardiopulmonary bypass. Six months following
repair, he continued to have normal PVRi of 2.2 WU/m2
and mPAP of 17mmHg (Table 1). He has now been
followed for ten months after corrective operation. The tre-
prostinil has been discontinued and he remains on bosentan
and sildenafil. The decision to discontinue treprostinil was
made balancing his excellent clinical progress with the lack
of availability of this drug in Mexico. Following his surgery,
he has had remarkable catch-up growth for both weight and
height, and now has a Z-score of –0.07 for weight and –0.87
Table 1. Cardiac catheterization data for Patient EJ.
Age
PAH-specific
therapies Condition
PAP (Sys/
Dia/Mean,
mmHg)
PVRi
(WU/m2)
CI (mL/
min/m2) Qp:Qs
Systemic
O2 Sat (%) PVR:SVR
5 years 1 month Sildenafil, oxygen FiO2 1.0, iNO
20 ppm
55/35/m45 7 0.76:1 60 0.92
5 years 8 months Sildenafil, bosentan,
treprostinil, oxygen
2L NC oxygen 38/13/m24 2.1-2.8 3.8 1.8:1 81 0.2
6 years 3 months
(post-repair)
Sildenafil, bosentan,
treprostinil
Room air 26/11/m17 2.2 3.3 1:1 96 0.16
748 | Pushing the envelope Kameny et al.
for height. He has also had improvement in development, as
he attends kindergarten and is now walking and active.
Case 2: hypoplastic left heart syndrome with
pulmonary vascular disease
AT was born at 36 weeks’ gestation with prenatally diag-
nosed high-risk hypoplastic left heart syndrome (HLHS)
with mitral stenosis, aortic atresia, and a restrictive atrial
septum. She initially underwent palliative surgery on her
third day of life consisting of bilateral branch pulmonary
artery bands and was continued on prostaglandin infusion
to maintain ductal patency. At three weeks of age, cardiac
catheterization revealed discrete left lower pulmonary vein
stenosis as well as diffuse narrowing of the left upper and left
lingular pulmonary veins with a 5-mmHg gradient without
focal stenosis. Given these findings, she was not considered
to be a good candidate for further surgical palliation.
Prostaglandin infusion was discontinued and she was dis-
charged home with palliative care on nasogastric feeds, ent-
eral furosemide, and home oxygen therapy.
She presented to our institution aged seven months with
worsening desaturation but otherwise adequate growth and
development. Her ductus arteriosus remained widely patent.
A cardiac catheterization was then performed at the age of
eight months, which demonstrated a severely restrictive
atrial septum with a left atrial pressure of 37mmHg and
compromised pulmonary blood flow with Qp:Qs 0.6:1.
The right pulmonary artery was not entered and so total
PVRi could not be calculated. There was no evidence of
pulmonary vein stenosis at this catheterization. A 6-mm
atrial stent was placed with a decrease in LA pressure to
15mmHg and an increase in Qp:Qs to 1.6:1. Given the bilat-
eral pulmonary bands, there were differential distal PAPs
and differential pulmonary blood flow. At this time, both
her transpulmonary gradient (17mmHg pre, 54mmHg post
stent placement) and her total PVRi (8.94 WU/m2 post
stent) were significantly elevated (Table 2). Note that the
total resistance was calculated using the relative flows to
each lung determined by the flow scan performed later
and described below.
Following this procedure, she was started on bosentan
titrated to 2mg/kg BID and treprostinil subcutaneously
titrated to 79 ng/kg/min. Given her history of gastro-
esophageal reflux, sildenafil therapy was not initiated.
A follow-up cardiac catheterization two months later
demonstrated continued restriction of the atrial septum,
which was balloon dilated. PVRi remained elevated at
4.03 WU/m2 (Table 2). One month later, a pulmonary
flow scan was performed, which demonstrated 61% pul-
monary blood flow to the left, 39% to the right. Repeat
catheterization at this time showed minimal residual gradi-
ent at the atrial septum and a total PVRi of 4.62 WU/m2 on
room air, which improved to 1.76 WU/m2 with iNO at
40 ppm and FiO2 1.0 (Table 2). With vasodilators, the trans-
pulmonary gradient was 16mmHg in the left lung and
3mmHg in the right lung. Pressures in the individual pul-
monary veins were measured and no stenosis was found.
Pulmonary vein angiography also confirmed the absence
of pulmonary vein stenosis.
She then underwent comprehensive stage 2 HLHS
palliative repair with pulmonary artery reconstruction,
atrial septostomy, PDA ligation, bidirectional Glenn, and
Norwood reconstruction of the neoaorta and aortic arch
with Damus-Kaye-Stansel anastomosis. Similar to the first
case, her subcutaneous treprostinil therapy was transitioned
to IV in the perioperative period. Sildenafil therapy was also
added to her regimen at this time. Her postoperative course
was complicated by a thrombus in her native ascending
aorta, which resolved on heparin therapy. She was dis-
charged on sildenafil, bosentan, treprostinil, and supplemen-
tal oxygen.
Table 2. Cardiac catheterization data for Patient AT.
Age PAH-specific Tx Condition
LAP
mmHg
Qp
L/min/m2
Qp left
lung
LPAP
mmHg
PVRi left
lung (WU/m2)
Qp right
lung
RPAP
mmHg
PVRi right
lung (WU/m2)
PVRi total
(WU/m2)
8 months –after
atrial stent
None Intubated FiO2 0.50 15 3.58 2.18 54 17.86 1.40 40 17.91 8.94
10 months Bosentan,
treprostinil oxygen
Intubated FiO2 0.21 12 4.00 2.44 35 9.43 1.56 23 7.05 4.03
11 months Bosentan,
treprostinil oxygen
Intubated FiO2 0.21 12 2.51 1.53 32 13.06 0.98 19 7.15 4.62
FiO2 1.0, iNO 40 ppm 12 3.38 2.06 28 7.76 1.32 15 2.28 1.76
15 months –
post Glenn
Sildenafil, bosentan,
treprostinil oxygen
FiO2 0.21 14 1.54 19 19 3.25
Post-coil
collaterals, FiO2 0.21
14 1.68 19 19 2.98
Left and right pulmonary blood flow are calculated based on a lung perfusion scan, which demonstrated 61% flow to left lung, 39% flow to right lung. PVRi (in
WU/m2) for each lung was then calculated using branch PAP distal to pulmonary band and relative flow. Total resistance was calculated using the formula:
1/RTOTAL¼ 1/RRightþ 1/RLeft. Using this calculation, the highest normal resistance of each lung (assuming normal blood flow distribution 45% left, 55% right)
would be RRight¼ 5.45 WU/m2, RLeft¼ 6.67 WU/m2, and PVRiTOTAL¼ 3 WU/ m2. Given that the left lung was relatively less protected by the pulmonary band (as
evinced by differential blood flow on perfusion scan), the differential elevation in resistance in the left lung is not surprising. The comprehensive stage 2 repair
included bilateral branch PA arterioplasty; thus, there was no residual pressure or flow differential in the branch pulmonary arteries.
LAP, mean left atrial pressure; LPAP, mean left pulmonary pressure; RPAP, mean right pulmonary pressure.
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She presented five months later following her comprehen-
sive stage 2 palliation with increasing head circumference
and lower systemic saturations. Cardiac catheterization at
that time demonstrated an elevated Glenn pressure
(19mmHg) with elevated atrial pressures (14mmHg) and
significant tricuspid valve regurgitation. In additional, one
venovenous collateral was identified and coiled, and mul-
tiple aortopulmonary collaterals were embolized. Her
PVRi was calculated as 3.25 WU/m2 at the beginning of
the catheterization and 2.98 WU/m2 following intervention
(Table 2), both within normal limits for a patient with Glenn
physiology. She then underwent repair of her tricuspid valve
with mild improvement in valve regurgitation. She was also
started on carvedilol in the setting of moderate right ven-
tricular systolic dysfunction. Her most recent echocardio-
gram demonstrated mildly diminished right ventricular
systolic function.
Discussion
These cases demonstrate good short-term outcomes in
patients with complex CHD treated aggressively with pul-
monary vasodilators preoperatively, who had previously not
been considered operative candidates owing to advanced
PVD at initial presentation. While these results are encoura-
ging, caution is warranted in applying this ‘‘treat and
repair’’ strategy more broadly. Lung biopsies were not
obtained in these patients at the time of operation; thus,
the histologic status of their pulmonary vascular pathology
is unknown. The long-term outcomes for these patients are
not known, and there is possibly a risk of progression of
underlying PVD. In particular, patients with elevated pul-
monary venous/left atrial pressures associated with CHD
often have mixed PAH with added post-capillary vascular
disease, as was the case for both of our patients. The natural
history of PVD associated with these complex lesions fol-
lowing surgical repair or palliation is unknown.
One case series from China is intriguing in assessing the
long-term viability of a treat and repair strategy in patients
with PH associated with CHD.10 This group treated 49
patients with Eisenmenger physiology with advanced PH
therapies—both those with simple shunt lesions (atrial and
ventricular septal defects, PDA) and with transposition of
the great arteries. They did not present cardiac catheteriza-
tion data, but rather relied on an increase in systemic oxygen
saturation (reflective of increased Qp:Qs) as a response to
therapy before undertaking surgical correction. They report
excellent outcomes with no reported deaths, even among the
two patients in the series with advanced pulmonary vasculo-
pathy (plexiform lesions) from lung biopsies taken at the
time of surgical correction. Apart from this large case
series, the treat and repair strategy for patients with PVD
and CHD is reported in the literature as case reports.11–16
Additionally, the treat and repair concept was comprehen-
sively presented by Dimopoulos et al., who recently
reviewed a series of case reports and outlined the principles
of this strategy, suggesting it may be applied in select
cases.17 Importantly, these cases were patients with simple
shunt lesions, while the cases presented here represent more
complex congenital disease.
In implementing this treatment strategy, it is critical that
these high-risk patients be cared for in a center with
advanced pediatric PH services, including coordinated con-
genital cardiac surgery, cardiology, critical care, and ancil-
lary services. Myriad factors will put these patients at
particular risk for progression of PVD, including the size
and type of defect, the degree of obstruction to pulmonary
venous flow or left atrial hypertension, delayed referral, or
the presence of associated syndromes (particularly Down
syndrome).18 Given the heterogeneity of complex cardiac
lesions and associated defects, it is unlikely that a single
set of guidelines will ever be comprehensive enough to
include all clinical scenarios. However, successful treatment
of these patients involves several critical aspects including
normalization of PVR prior to surgical correction and
aggressive surgical or procedural intervention on residual
lesions. Importantly, the timing between aggressive medical
therapy and surgical intervention was as brief as possible,
once the patient’s hemodynamics were favorable. Notably,
we feel that these cases highlight the additive value of
repeated cardiac catheterization in addition to other non-
invasive modalities. Finally, for patients with uncorrected
CHD lesions, it is evident that lowering PVR in the absence
of a fixed anatomic obstruction to pulmonary blood flow
will lead to elevation of Qp:Qs, which not only increases
acute metabolic demand but also exposes the pulmonary
vasculature to the injurious effects of increased flow.19
Here, the PH and congenital cardiac surgical teams must
be nimble in their management to optimize outcomes.
In addition to appropriate patient selection for this treat
and repair strategy, another vexing clinical question is the
ongoing management of specific PH therapies postopera-
tively. In our first case, practical considerations – the fam-
ily’s impending move to Mexico – necessarily impacted
clinical decision-making in the timing of discontinuing
therapies. Even in this setting, therapies were stepped
down with great caution and repeated catheterization evalu-
ations; additionally, the patient will remain on some pul-
monary vasodilator therapy (sildenafil and bosentan)
indefinitely. The timing of removing therapies, or the neces-
sity of removing them at all, remains an important unan-
swered clinical question.
In conclusion, patients with advanced PVD associated
with CHD represent a challenging clinical cohort. The
application of a novel treat and repair strategy for
patients whose presenting hemodynamics initially preclude
surgical correction or palliation is an appealing strategy
for patients who otherwise would have no viable thera-
peutic options. Care for these patients must be undertaken
with multidisciplinary input and great caution, including
tempering patient and family expectations for long-term
outcomes in the absence of established data. Despite these
750 | Pushing the envelope Kameny et al.
cautionary statements, the strategy of aggressive medical
therapy with multiple drug classes followed by prompt
surgical repair once hemodynamics are normalized repre-
sents an exciting frontier in advancing care for patients
with PVD and PH.
Conflict of interest
The author(s) declare that there is no conflict of interest.
Funding
RJK is supported by the American Heart Association Fellow-to-
Faculty Grant (14FTF19670001).
References
1. Butrous G, Ghofrani H-A and Grimminger F. Pulmonary vas-
cular disease in the developing world. Circulation 2008; 118(17):
1758–1766.
2. Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung
biopsy in congenital heart disease: a morphometric approach
to pulmonary vascular disease. Circulation 1978; 58(6):
1107–1122.
3. Tefuarani N, Hawker R, Vince J, et al. Surgical programme at
Royal Alexandra Hospital, Sydney, for Papua New Guinea
children with congenital heart disease, 1978–1994. J Paediatr
Child Health 2002; 38(2): 178–182.
4. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a
preoperative test (INOP Test I): the INOP Test Study Group.
Circulation 2002; 106(12 Suppl 1): I76–81.
5. Kannan BRJ, Sivasankaran S, Tharakan JA, et al. Long-term
outcome of patients operated for large ventricular septal defects
with increased pulmonary vascular resistance. Indian Heart J
2003; 55(2): 161–166.
6. Lopes AA, Barst RJ, Haworth SG, et al. Repair of congenital
heart disease with associated pulmonary hypertension in chil-
dren: what are the minimal investigative procedures? Consensus
statement from the Congenital Heart Disease and Pediatric
Task Forces, Pulmonary Vascular Research Institute (PVRI).
Pulm Circ 2004; 4(2): 330–341.
7. Abman SH, Hansmann G, Archer SL, et al. Pediatric
Pulmonary Hypertension: Guidelines from the American
Heart Association and American Thoracic Society. Circulation
2015; 132(21): 2037–2099.
8. Adatia I. Pulmonary vascular disease. In: Freedom RM, Yoo
SJ, Mikailian H, et al (eds) The Natural and Modifed History of
Congenital Heart Disease. Elmsford, NY: Blackwell
Publishing, pp.518–527.
9. Viswanathan S and Kumar RK. Assessment of operability of
congenital cardiac shunts with increased pulmonary vascular
resistance. Catheter Cardiovasc Interv 2008; 71(5): 665–670.
10. Huang J-B, Liu Y-L, Yu C-T, et al. Lung biopsy findings in
previously inoperable patients with severe pulmonary hyper-
tension associated with congenital heart disease. Int J Cardiol
2011; 151(1): 76–83.
11. Eicken A, Balling G, Gildein HP, et al. Transcatheter closure
of a non-restrictive patent ductus arteriosus with an Amplatzer
muscular ventricular septal defect occluder. Int J Cardiol 2007;
117(1): e40–42.
12. Frost AE, Quin˜ones MA, Zoghbi WA, et al. Reversal of pul-
monary hypertension and subsequent repair of atrial septal
defect after treatment with continuous intravenous epoproste-
nol. J Heart Lung Transplant 2005; 24(4): 501–503.
13. Imanaka K, Kotsuka Y, Takamoto S, et al. [Atrial septal
defect and severe pulmonary hypertension in an adult who
needed nitric oxide inhalation after repair]. Kyobu Geka
1998; 51(5): 403–405.
14. Kim Y-H, Yu JJ, Yun T-J, et al. Repair of atrial septal defect
with Eisenmenger syndrome after long-term sildenafil therapy.
Ann Thorac Surg 2010; 89(5): 1629–1630.
15. Schwerzmann M and Pfammatter J-P. Approaching atrial
septal defects in pulmonary hypertension. Expert Rev
Cardiovasc Ther 2015; 13(6): 693–701.
16. Yamauchi H, Yamaki S, Fujii M, et al. Reduction in recalci-
trant pulmonary hypertension after operation for atrial septal
defect. ATS 2001; 72(3): 905–906. (discussion 906–907).
17. Dimopoulos K, Peset A and Gatzoulis MA. Evaluating oper-
ability in adults with congenital heart disease and the role of
pretreatment with targeted pulmonary arterial hypertension
therapy. Int J Cardiol 2008; 129(2): 163–171.
18. Giglia TM and Humpl T. Preoperative pulmonary hemo-
dynamics and assessment of operability: is there a pulmonary
vascular resistance that precludes cardiac operation? Pediatr
Crit Care Med 2010; 11(2 Suppl): S57–69.
19. Rosenzweig EB and Barst RJ. Congenital heart disease and
pulmonary hypertension: pharmacology and feasibility of
late surgery. Prog Cardiovasc Dis 2012; 55(2): 128–133.
Pulmonary Circulation Volume 7 Number 3 | 751
